

Application No.: 10/628,969
Docket No.: BB1107USCNT

Page 4

REMARKS

Claims 27-39 are now pending, with Claim 1 being the sole independent claim.
Claims 1-26 have been cancelled without prejudice to or disclaimer of the subject matter recited therein.

Claims 27-39 have been added.

Support in the specification for the term "transcriptional repressor activity" in claim 27 is found at least in the paragraphs at page 8, lines 22-30, and page 50, lines 24-33.

Support for the sequence identities recited in claims 27-29 is found at least in the paragraph beginning on line 23 of page 13 and continuing through line 5 of page 14 of the specification.

Support for the use of the term "recombinant" in claims 33, 35, and 37-39, is found at least in the paragraph at page 11, lines 19-21, of the specification.

Support for claim 39 is found at least in Example 10, pages 46-47, of the specification.

No new matter has been added.

Application No.: 10/628,969
Docket No.: BB1107USCNT

Page 5

RESPONSE TO RESTRICTION REQUIREMENT

Applicants hereby elect, without traverse, Group I, Claims 1-10 and 21-25, drawn to an isolated polynucleotide encoding a polypeptide, a chimeric gene and vector comprising said polynucleotide, methods for transforming cells comprising said polynucleotide and cells and plants comprising said polynucleotide, classified in class 800, subclass 278, for example, and SEQ ID NOs:31 and 32.

The amino acid sequence of SEQ ID NO:32 is encoded by nucleotides 55-828 of SEQ ID NO:31.

Applicants believe new claims 27-39 to be directed to Group I.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



EMIL M. OROZCO, JR.
AGENT FOR APPLICANTS
Registration No. 50,823
Telephone: 302-695-3121
Facsimile: 302-892-1026

Dated: May 15, 2006